Donna Swanson, APRN Nurse Practitioner - Psych/Mental Health Medicare: Not Enrolled in Medicare Practice Location: 274 Granville Rd, North Granby, CT 06060 Phone: 860-693-8831 |
News Archive
Ascenta Therapeutics announced today the signing of a global collaboration and licensing agreement with sanofi-aventis covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death). These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor function and potentially enhancing cancer control and treatment.
Breast cancer is the most common cancer among American women (except for skin cancers). One in eight women in the United States will develop invasive breast cancer during their lifetime with an estimated 252,710 new cases of invasive breast cancer in 2017.
Quintiles today announced a comprehensive suite of biomarker assays to help biopharmaceutical companies investigate the phosphoinositide 3-kinases (PI3K) cancer survival pathway, the focus of numerous anti-cancer therapies under development. Understanding the PI3K pathway is essential in developing new medicines to inhibit or block this pathway, thereby cutting off a metabolic function needed for certain cancers to survive.
Scientists have discovered a key 'survival gene' that prevents strains of tuberculosis (TB) from mutating into drug-resistant 'superbugs'.
PROLOR Biotech, Inc., today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering the company's CTP platform, which has the potential to extend the duration of activity of virtually all therapeutic proteins.
› Verified 6 days ago